Department of Diagnostic and Interventional Radiology, Eberhard Karls University, Hoppe-Seyler-Strasse 3, 72076, Tübingen, Germany.
Department of Radiology, Kantonsspital Frauenfeld, Pfaffenholzstrasse 4, CH-8501, Frauenfeld, Switzerland.
Eur J Radiol. 2021 Jul;140:109768. doi: 10.1016/j.ejrad.2021.109768. Epub 2021 May 8.
The objective of this retrospective single centre study was to evaluate the impact of intraprocedural cone-beam CT with parenchymal blood volume assessment (PBV-CBCT) for guidance of transarterial chemoembolization with drug-eluting beads (DEB-TACE) in HCC patients on the effectiveness (local tumour response, survival and number of individual TACE sessions) compared to guidance solely by digital subtraction angiography (DSA).
n = 179 HCC patients (mean age, 77.4 y) undergoing DEB-TACE, with (n = 28) and without (n = 151) PBV-CBCT, using 100-300 μm microspheres loaded with epirubicin were retrospectively analysed. Tumour response according to mRECIST, overall survival and number of TACE interventions as well as laboratory parameters for liver function and inflammation were recorded. The analysis of the influence of intraprocedural PBV-CBCT was based on matched pair analysis (CBCT n = 28 vs. DSA n = 28). Gender, tumour number, tumour size and HCC risk factors were equally distributed between both groups.
Response rates according to mRECIST:CBCT: PD: 7%, SD: 28 %, PR: 46 %, CR: 18 %; DSA: PD: 7 %, SD: 32 %, PR: 39 %, CR: 21 % (p = 0.174). Median OS: CBCT: 44.1 months; DSA: 28.8 months (p = 0.815). Median TACE number: CBCT: 2.0; DSA: 3.0 (p = 0.046).
The use of intraprocedural PBV-CBCT for TACE guidance reduced the number of re-interventions, with no negative effects on tumour response and overall survival. The study findings support the use of PBV-CBCT for DEB-TACE guidance as the improved immediate feedback leads to a considerable increase of the treatment efficiency and helps to avoid unnecessary re-interventions.
本回顾性单中心研究的目的是评估对比单纯数字减影血管造影(DSA)引导下经动脉化疗栓塞术(TACE)与术中锥形束 CT 联合血容量评估(PBV-CBCT)引导下载药微球 TACE(DEB-TACE)治疗肝细胞癌(HCC)患者的疗效(局部肿瘤反应、生存和 TACE 次数)。
回顾性分析 179 例接受 DEB-TACE 治疗的 HCC 患者(平均年龄 77.4 岁),其中 28 例(PBV-CBCT 组)和 151 例(非 PBV-CBCT 组)患者使用载表阿霉素 100-300μm 微球。根据 mRECIST 标准评估肿瘤反应、总生存率和 TACE 干预次数以及肝功能和炎症的实验室参数。术中 PBV-CBCT 影响的分析基于匹配对分析(CBCT n=28 与 DSA n=28)。两组患者的性别、肿瘤数量、肿瘤大小和 HCC 危险因素分布均衡。
mRECIST 标准评价的肿瘤反应率:CBCT 组:PD(疾病进展)7%,SD(疾病稳定)28%,PR(部分缓解)46%,CR(完全缓解)18%;DSA 组:PD 7%,SD 32%,PR 39%,CR 21%(p=0.174)。中位 OS:CBCT 组 44.1 个月,DSA 组 28.8 个月(p=0.815)。中位 TACE 次数:CBCT 组 2.0 次,DSA 组 3.0 次(p=0.046)。
术中 PBV-CBCT 用于 TACE 引导可减少再次介入治疗的次数,且对肿瘤反应和总生存率无负面影响。研究结果支持 PBV-CBCT 用于 DEB-TACE 引导,因为即时反馈的改善可显著提高治疗效率,避免不必要的再次介入治疗。